Personalis, Inc. (NASDAQ:PSNL) Q4 2023 Earnings Call Transcript

Christopher Hall: No, but to be clear, we’re focused on our own commercial energy and traction, and then with them, we’re focused on breast cancer. We’re focused on IO-therapy monitoring, and we’re focused on lung cancer. And as part of the agreement, they have exclusivity on those three areas, and that’s what we’re focused on now. And so, that’s the messaging, that’s the type of doctor that we call on, and that’s what we’re focusing on. We’re seeing a good chunk of our samples there. Now, I’d be kidding if I said everything within those three indications, because we get other stuff coming through the system, and we’ve got to manage through that the best we can, but we’re staying laser focused on these indications, and as we go through the – so we’ll go through the next several months and in a few years.

Remember that, the strategy here was to focus on the indications where we thought we could gain significant traction with an ultra-sensitive approach and add really tremendous value by finding cancer earlier, allowing us to escalate patients to therapy quicker that actually could yield big results. And secondarily, because if you’re flying blind, you do therapies and you do invasive procedures that a patient may not get benefit from, but because you don’t know who does and doesn’t, then you do it. And so we have the opportunity to deescalate patients, and that’s especially true in breast cancer. So that’s where we’re focused and building that. We think that from an investor standpoint, that covers a good chunk of the market to be quite frank.

I mean, it’s not like these are esoteric parts of the MRD market. This is where a good chunk of the patients are. There’s several hundred thousand patients a year that are on IO-therapy and that are being monitored and that breast cancer is one of the biggest cancers, and lung cancer is one of the biggest cancers. And so those three indications together, we think cover a good significant portion of the $20 billion expected market that we feel like we’re conditioned to hit it well with this approach and in a cost-effective manner rather than building evidence across every single clinical indication simultaneously.

Unidentified Analyst: Got you. Makes sense. Well, thanks for taking our questions. Much appreciated.

Christopher Hall: Thanks, Joe.

Operator: Thank you, ladies and gentlemen. This concludes today’s teleconference. You may disconnect your line at this time. Thank you for your participation and have a great day.

Christopher Hall: Awesome. Thanks.

Operator: Goodbye.